Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Magellan Pharmacy Services, Inc. $200 Million Term Loan
Davis Polk advised the administrative agent in connection with a $200 million delayed draw term loan facility for…
Sucampo Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering
Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo…
Davis Polk Advises Roche on Its $250 Million Cash Tender Offer
Davis Polk advised Roche Holdings, Inc. in connection with a cash tender offer for up to $250 million aggregate principal…
Achaogen, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of…
Yestar International Holdings Company Limited Placement of Shares
Davis Polk advised the sole placing agent in connection with the placing of 38,500,000 shares held by China Asset Management…
Xencor, Inc. Follow-On Offering
Davis Polk advised the sole book-running manager in connection with the $126.5 million public offering of common stock of…
Evolent Health Convertible Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million…
Teleflex Acquires Vascular Solutions
Davis Polk is advising JP Morgan as financial adviser to Teleflex Incorporated in connection with its approximately $1…
Davis Polk Advises Roche on Its Sale of Florence, South Carolina, Manufacturing Site to Patheon
Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing…
Abbott Laboratories $15.1 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion…